Rebiotix has received fast-track designation from the FDA for its fecal transplant, which could speed up marketing approval for the product. The Roseville, Minn.-based biotech startup intends to use the product for patients with Clostridium difficile, a type of hospital-acquired bacterial infection.
FDA grants fast-track status to Rebiotix's stool transplant
SmartBrief Job Listings for Health Care
|Senior Research Analyst||
America's Health Insurance Plans (AHIP)
|Manager, Regulatory Affairs||
|Washington DC, DC|
|Senior Counsel - FDA Regulatory Affairs||
|Director, Quality Assurance||
|Provider Relations Manager||
Breakthrough Behavioral, Inc.
|Redwood City, CA|